罗普司亭治疗再生障碍性贫血的机制与临床应用研究进展  

Research progress on the mechanism and clinical application of romiplostim in the treatment of aplastic anemia

作　　者：李洋洋 高明洁[2] 田飞[2] 孙伟正(综述)[2] 王金环(审校)[2] Li Yangyang;Gao Mingjie;Tian Fei;Sun Weizheng;Wang Jinhuan(Heilongjiang University of Chinese Medicine,Heilongjiang Province,Harbin 150040,China;不详)

机构地区：[1]黑龙江中医药大学,哈尔滨150040 [2]黑龙江中医药大学附属第一医院血液病科

出　　处：《疑难病杂志》2024年第4期504-508,共5页Chinese Journal of Difficult and Complicated Cases

基　　金：国家自然科学基金资助项目(81673968);中国民族医药学会科研项目(2021Z1161-440102)。

摘　　要：再生障碍性贫血(AA)是一种严重的造血系统疾病,临床上以全血细胞减少和骨髓造血功能受损为特征。罗普司亭作为一种Janus激酶抑制剂,近年来引起了广泛的关注。文章从多个角度对罗普司亭治疗AA的机制与临床应用展开了全面而深入的讨论,包括该药物在治疗过程中的作用机制、免疫调节作用以及潜在的不良反应和安全性考量。并展望个体化治疗策略的发展和新型治疗靶点的探索,为该领域的进一步研究提供有益的思路。Aplastic anemia(AA)is a severe hematologic disorder characterized clinically by a reduction in all blood cell types and impairment of bone marrow hematopoiesis.Romiplostim,as a Janus kinase inhibitor,has garnered widespread attention in recent years.This paper comprehensively and thoroughly discusses the mechanisms and clinical applications of romiplostim in the treatment of aplastic anemia from various perspectives.It explores the drug's mechanisms of action during the treatment process,its immunomodulatory effects,and potential side effects and safety considerations.Furthermore,the paper also outlines future research directions,particularly the development of personalized treatment strategies and the exploration of novel therapeutic targets,providing valuable insights and prospects for further advancements in the field.

关 键 词：再生障碍性贫血 罗普司亭 Janus激酶抑制剂 治疗 研究进展 

分 类 号：R551.3[医药卫生—血液循环系统疾病] R453.9[医药卫生—内科学]